louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01039935: Genetic Basis of Odor Discrimination
Official title: Genetic Basis of Odor Discrimination
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-smokers
Keywords: Odor Discrimination
Lead sponsor: Rockefeller University
Sponsor class: OTHER
First posted: 2009-12-25
Enrollment: 512
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Healthy volunteers

Brief summary: Prior to the main study we will perform a pilot study on 60 subjects. The purpose of the pilot study is to identify the range of odor concentrations that will be used in the main study and to optimize the tasks performed in the main study.


Eligibility criteria: Inclusion Criteria:

1. Age 18-50
2. Current non-smokers

Exclusion Criteria:

1. Current smokers
2. Allergy to fragrances or smells of any kind
3. Active head cold, upper respiratory infection, or seasonal nasal allergies
4. History of nasal health problems, including endoscopic nasal surgery for sinus conditions or polyp removal.
5. Pre-existing medical condition that has caused anosmia or near total loss of the sense of smell, such as: head injury, cancer therapy, radiation to head and neck, or alcoholism

Primary outcomes:
measure: Percentage of correct responses when discriminating between (-)-carvone and (+)-carvone, isovaleric acid and isobutyric acid, androstenone and androstadienone DNA sequence of ORs sensitive to these odors
timeFrame: 3 years
Secondary outcomes:
measure: concentration at which odors need to be added to allow for discrimination; thresholds to all six odors; verbal descriptors assigned to all six odors
timeFrame: 3 years
Other outcomes:
Locations:
city: New York
country: United States
facility: The Rockefeller University
state: New York
Study officials:
affiliation: The Rockefeller University
name: Leslie Vosshall, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03322735: Study of BCMA CAR-T in Multiple Myeloma
Official title: A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Multiple Myeloma
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
Collaborators: name: The Pregene (ShenZhen) Biotechnology Company, Ltd.
First posted: 2017-10-26
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to infusion BCMA CAR-T cells to the patients with relapsed and refractory multiple myeloma(MM), to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the MM cells through the recognition of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.


Eligibility criteria: Inclusion Criteria:

* 1. 18 years to 70 years, expected survival \> 3 months;
* 2. Confirmed diagnosis of active MM as defined by IMWG. BCMA expression of the malignant cells must be detected by immunohistochemistry or by flow cytometry.
* 3. BCMA-expressing B cell malignancy must be assured and must be relapsed or refractory disease.；
* 4. ECOG performance status of 0-2;
* 5. Cardiac function: 1-2 levels; Liver: TBIL≤3ULN，AST ≤2.5ULN，ALT ≤2.5ULN; kidney: Cr≤1.25ULN;
* 6. No serious allergic constitution;
* 7. No other serous diseases that conflicts with the clinical program;
* 8. No other cancer history;
* 9. female participants of reproductive potential must have a negative serum pregnancy test;
* 10. Subjects must have signed written, informed consent.

Exclusion Criteria:

* 1. Pregnant or lactating women;
* 2. Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
* 3. Active hepatitis B or hepatitis C infection;
* 4. Recent or current use of glucocorticoid or other immunosuppressor;
* 5. serious mental disorder;
* 6. With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
* 7. Participate in other clinical research in the past three months; previously treatment with any gene therapy products;

Primary outcomes:
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: 1 year
Secondary outcomes:
measure: Persistence of the BCMA CAR+ T cells
timeFrame: 1 year
measure: anti-tumor responses of BCMA CAR-T cells
timeFrame: 1 year
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Cancer Hospital Affiliate to Zhengzhou University & Henan Cancer Hospital
state: Henan
Study officials:
affiliation: Henan Cancer Hospital
name: Yongping Song
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00911235: The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
Official title: An Open-Label, Randomized, Two-Way Crossover Study To Evaluate The Effect Of Fluconazole, A Moderate CYP3A4 Inhibitor, On The Single-Dose Pharmacokinetics Of Fesoterodine In Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence
Keywords: The Effect Of Fluconazole On Pharmacokinetics Of Fesoterodine In Healthy Subjects
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2009-06-01
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study is designed to estimate the effect of fluconazole (200 mg BID for 2 days), a moderate CYP3A4 inhibitor on the pharmacokinetics of a single 8 mg oral dose of fesoterodine in healthy adult subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy subjects between the ages of 18 and 55 years

Exclusion Criteria:

* Not healthy subjects. subjects with acute or chronic medical or psychiatric condition or laboratory abnormality

Primary outcomes:
measure: AUCinf and Cmax of 5-HMT
timeFrame: 3 days per period
Secondary outcomes:
measure: AUClast, Tmax and half-life of 5-HMT as data permit.
timeFrame: 3 days per period
measure: Safety will be assessed by subjective symptoms/objective findings including physical examination findings, clinical safety laboratory assessments and adverse event monitoring.
timeFrame: 3 days per period
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Pfizer Investigational Site
state: Connecticut
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT02477735: The Effect of Tympanostomy Tube Insertion on Sleep in Children With Chronic Otitis Media With Effusion
Official title: The Effect of Tympanostomy Tube Insertion on Sleep in Children With Chronic Otitis Media With Effusion
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Otitis Media With Effusion
Sleep Disturbances
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2015-06-23
Enrollment: 30
Sex: ALL
Minimum age (years): 6
Maximum age (years): 36
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Infants with COME who will be referred for TTI.

Brief summary: The purpose of this study is to investigate the prevalence of sleep disturbances in children with Chronic Otitis Media with Effusion (COME) and the effect of tympanostomy tube insertion (TTI) on sleep disturbances.

Detailed description: Comparison of sleep disturbances will be between infants with Chronic Otitis Media with Effusion (COME) who will be referred for tympanostomy tube insertion (TTI) (study group) and healthy infants that were recruited from the community well-baby clinics (control group).

To evaluate sleep patterns, parents of the study group will complete two validated sleep questionnaires assessing the infant's typical sleep patterns based on parental reports. A week before TTI and 1 week to 1 month after the surgery, sleep will be evaluate by actigraph for a week long.

Eligibility criteria: Inclusion Criteria:

* Age: 6-36 months
* Referred for tympanostomy tube insertion as a treatment for COME.

Exclusion Criteria:

* Snoring and sleep disordered breathing (SDB)
* Chronic medical condition
* referred for TTI and adenoidectomy/tonsillectomy

Primary outcomes:
measure: Actigraphy measurements
timeFrame: Up to two years
Secondary outcomes:
measure: OSA-18 questionnaire score
timeFrame: Up to two years
measure: Brief Infant Sleep Questionnaire (BISQ) score
timeFrame: Up to two years
Other outcomes:
Locations:
city: Tel-Aviv
country: Israel
facility: "DANA" children's hospital
Study officials:
affiliation: Dana Children's Hospital, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine Tel-Aviv Univesity, Israel
name: Gad Fishman, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01368835: Evaluation of the Ulthera™ System for Obtaining Lift and Tightening of the Cheek Tissue
Official title: Evaluation of the Ulthera™ System For Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mild to Moderate Skin Laxity on Cheek
Mild to Moderate Skin Laxity on Upper Neck
Mild to Moderate Subcutaneous Fat on Cheek
Mild to Moderate Subcutaneous Fat on Upper Neck
Lead sponsor: Merz North America, Inc.
Sponsor class: INDUSTRY
Collaborators: name: University of Texas Southwestern Medical Center
First posted: 2011-06-08
Enrollment: 103
Sex: ALL
Minimum age (years): 35
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The clinical trial evaluates the clinical outcomes associated with the non-invasive treatment to obtain lift and tightening of the cheek tissue and improve jawline definition and submental skin laxity utilizing the Ulthera™ System which delivers ultrasound energy in a focused manner below the surface of the skin

Detailed description: The primary objective of this study is to demonstrate the effectiveness of the Ulthera™ System for the non-invasive dermatological treatment to obtain lift and tighten the cheek tissue.

The secondary objective of this study is to demonstrate the effectiveness of the Ulthera™ System for the non-invasive dermatological treatment for improvement in jawline definition and submental skin laxity at 3 and 6 months compared to baseline based on the consensus of the three masked reviewers.

Eligibility criteria: Inclusion Criteria:

* Male or female, aged 35 to 60 years
* Subject in good health
* Desire lift and tightening of cheek tissue, improvement of jawline definition or submental skin laxity

Exclusion Criteria:

* Pregnant or lactating
* Has an active systemic or local skin disease that may alter wound healing
* Severe solar elastosis
* Excessive subcutaneous fat on the cheeks
* Excessive skin laxity on the lower face and neck
* Has significant scarring in areas to be treated
* Has significant open facial wounds or lesions
* Has severe or cystic acne on the face

Primary outcomes:
measure: Change in Overall Lifting and Tightening of Treated Tissue on the Lower Face and Submental Regions.
timeFrame: 90D
Secondary outcomes:
measure: Change in Submental and Neck Skin Laxity by Quantitative Analysis
timeFrame: 90D
measure: Patient Satisfaction Questionnaire
timeFrame: 90D
Other outcomes:
measure: Subject Assessment of Pain
timeFrame: During Ulthera study treatment
Locations:
Study officials:
affiliation: University of Texas Southwestern Medical Center
name: Jeffrey M. Kenkel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02287935: Limberg and Karydakis Flap in Recurrent Pilonidal Sinus Disease
Official title: Effectiveness of Limberg and Karydakis Flap in Recurrent Pilonidal Sinus Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Recurrent Pilonidal Sinus Disease
Keywords: Karydakis procedure
Limberg flap
recurrent pilonidal sinus
Lead sponsor: Adana Numune Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2014-11-11
Enrollment: 71
Sex: ALL
Minimum age (years): 16
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It was investigated whether there is a factor that can aid determination of the preferred technique by comparing the early Limberg flap and Karydakis procedure techniques for the treatment of recurrent pilonidal sinus.

Detailed description: Sacrococcygeal pilonidal sinus is common in young men and may recur overtime after surgery.

It was investigated whether there is a factor that can aid determination of the preferred technique by comparing the early Limberg flap and Karydakis procedure techniques for the treatment of recurrent pilonidal sinus.

Eligibility criteria: Inclusion Criteria:

1. Patients willing to give written informed consent
2. There should be recurrent pilonidal sinus

2. Recurrent adult patients (over 18 years of age) undergoing surgery for pilonidal sinus

3. International normalizing ratio (INR) less than 1.5

4. Prothrombin time (PT) should be less than 15 s

5. Partial thromboplastin (PTT) time should be near normal

6. Platelet count should be greater than 50,000 per mm3 to limit the risk of bleeding

7. There must be no infection at the time of surgery

-

Exclusion Criteria:

1. Patients not willing to give informed consent
2. Age less than 16 years
3. Patient presenting with conditions mimicking pilonidal sinus
4. Diabetes mellitus, renal failure, immunosuppression e.g. were excluded

   -

Primary outcomes:
measure: Superiority of Limberg Flap in Recurrent Pilonidal Sinus Disease
timeFrame: January 2009 to December 2013, Patients were invited for control 1 month, 3 months, 6 months, 1 year intervals
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Bali I, Aziret M, Sozen S, Emir S, Erdem H, Cetinkunar S, Irkorucu O. Effectiveness of Limberg and Karydakis flap in recurrent pilonidal sinus disease. Clinics (Sao Paulo). 2015 May;70(5):350-5. doi: 10.6061/clinics/2015(05)08. Epub 2015 May 1.
Clinical trial NCT04670458: Derivation of An In-Hospital Cardiac Arrest Prediction Model for Patients in Intensive Care Unit
Official title: Derivation of An In-Hospital Cardiac Arrest Prediction Model for Patients in Intensive Care Unit
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: In-Hospital Cardiac Arrest
Keywords: Critically ill patients
In-Hospital Cardiac Arrest
Early recognition
Early warning score
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2020-12-17
Enrollment: 2000
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients hospitalized in the intensive care unit (ICU, CCU, RICU, EICU, NCU and DICU) of Qilu Hospital of Shandong University from January 1, 2017 to October 31, 2019 were selected.

Brief summary: Current studies have shown that hospitalized ICU patients have a high risk of IHCA, with an incidence of about 0.6-7.8%. Early prediction of the occurrence of IHCA in severe patients can provide early intervention, prevent the deterioration of the disease, and reduce the incidence of IHCA. Therefore, researchers wanted to verify the efficacy of MEWS, NEWS, and CART scores in predicting IHCA in ICU inpatients, and to establish an early-warning scoring model that could effectively predict the risk of IHCA occurrence in ICU inpatients during hospitalization.


Eligibility criteria: CA group

Inclusion Criteria:

* Occurrence of IHCA
* Hospital stay ≥48h.

Exclusion Criteria:

* \<14 years
* Do Not Resuscitat
* Patients hospitalized due to out-of-hospital cardiac arrest
* Cardiac arrest occurs during the operation
* The patients with implanted cardiac pacemaker suffered cardiac arrest due to instrument malfunction.

CONTROL group

Inclusion Criteria:

* Without IHCA
* Hospital stay ≥48h

Exclusion Criteria:

* \<14 years
* Leave hospital without medical advice

Primary outcomes:
measure: In-Hospital Cardiac Arrest
timeFrame: Day 2
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu Hospital of Shandong University
state: Shandong
Study officials:
References:
Clinical trial NCT01633658: The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3
Official title: The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3 Compared to Native Vitamin D3: A Short Term Pharmacokinetic Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Vitamin D Deficiency
Keywords: vitamin D
Lead sponsor: Creighton University
Sponsor class: OTHER
First posted: 2012-07-04
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The investigators hypothesize that native vitamin D will have more variability in 25(OH)D dose response when compared to a given equipotent dose of 25-hydroxyvitamin D3. This will be a single blind, active control, pharmacokinetic study of 625 μg 25(OH)D given orally or 2500 μg native vitamin D given orally.

Detailed description: Single blind, active control, pharmacokinetic study of 625 μg 25(OH)D given orally or 2500 μg native vitamin D given orally.

Eligibility criteria: Inclusion Criteria:

* Ten men and women in each group,
* aged 20-60.

Exclusion Criteria:

* History of hypercalcemia,
* vitamin D supplement use \> 800 IU daily,
* BMI \> 30,
* gastrointestinal malabsorption (from celiac sprue, colitis, surgery, etc.), kidney disease or liver disease,
* use of steroids in any form,
* anticonvulsants,
* antibiotics,
* acute illness, or
* vacation planned to "sunny climate"

Primary outcomes:
measure: Serum 25(OH)D response
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Omaha
country: United States
facility: Creighton University
state: Nebraska
Study officials:
affiliation: Creighton University
name: Laura Armas, MD,MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02734758: Markers of Atrial Fibrillation
Official title: Atrial Fibrillation in Ischemic Stroke: Strengthening Identification and Decisions to Anticoagulate
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stroke
Atrial Fibrillation
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2016-04-12
Enrollment: 131
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with ischemic stroke

Brief summary: This study will evaluate whether a gene marker can improve the identification of atrial fibrillation in patients with ischemic stroke, and evaluate whether the decision to anticoagulate could be improved by a marker of atrial fibrillation.

Detailed description: Atrial fibrillation (AF) is a major cause of ischemic stroke that is critical to identify because anticoagulation provides a 66% risk reduction in recurrent stroke. However, opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and therefore not detected at the time of stroke. In addition, even when AF is identified anticoagulation may not be initiated due to perceived contraindications.

This study will (1) evaluate whether a gene marker can improve the identification of AF in patients with ischemic stroke, and (2) evaluate decisions by health care provider and patients to anticoagulate AF, and whether this decision could be improved by a marker of AF at time of stroke. An AF Gene Score will be developed comprised of genes associated with inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid identification of stroke due to AF which may increase initiation of anticoagulation therapy. This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty regarding the association of delayed AF with initial stroke and delays anticoagulation.

Eligibility criteria: Inclusion Criteria:

* Ischemic stroke within 72 hours of onset
* Complete evaluation to determine cause of stroke
* Informed Consent

Exclusion Criteria:

* Active Infection
* Lymphoma / Leukemia / Blood dyscrasia
* Hemorrhagic stroke
* Immunosuppressive therapy
* Illicit drug use
* Blood transfusion +/- 1 month
* Major surgery/trauma in last 6mts

Primary outcomes:
measure: Gene expression
timeFrame: Post stroke through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis
state: California
Study officials:
References:
Clinical trial NCT02448758: Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)
Official title: Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Non-Small Cell Lung Cancer
Keywords: mutation
Lead sponsor: Centre Oscar Lambret
Sponsor class: OTHER
Collaborators: name: University Hospital, Lille
name: Centre de Biologie Pathologie : Plateforme de Biologie Moléculaire de Lille
First posted: 2015-05-19
Enrollment: 785
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Non-small cell lung cancer with mutation of the Nord Pas de Calais

Brief summary: The investigators propose to create a database at the regional level, the principle is to include all patients in whom a mutation was detected from a single platform (Lille). The creation of this regional cohort, smaller than the national cohort of Biomarkers France, will perform a more comprehensive collection of clinical data, and molecular monitoring data of patients included. To increase the completeness of the collection of information, it will not be based on voluntary prescribing clinician but will be largely carried out by CRA dedicated to this activity.

Detailed description: This is a prospective and retrospective study of a population of patients with mutated non-small cell lung cancer in the Nord Pas de Calais. Retrospective cohort will involve patients with main molecular abnormalities, identifiable from molecular biology platform CRRC, except EGFR and KRAS treated from September 2011 to February 2013.

Eligibility criteria: Inclusion Criteria:

* Aged ≥ 18 years old
* Patient with non-small cell lung cancer
* Detected in the Nord Pas de Calais
* Monitored in the Nord Pas de Calais
* Patient must have signed a non-opposition form to the use of medical data

Exclusion Criteria:

- No identified mutation

Primary outcomes:
measure: Correlation between clinical factors and mutation status
timeFrame: at baseline
Secondary outcomes:
measure: Progression-free survival
timeFrame: 3 years
measure: Overall survival
timeFrame: 3 years
measure: Number of patients included in a clinical trial dedicated to a certain type of non-small cell lung cancer with mutation
timeFrame: 3 years
measure: Number of cases per mutation type
timeFrame: 3 years
Other outcomes:
Locations:
city: Lille
country: France
facility: Centre Oscar Lambret
city: Lille
country: France
facility: CHRU
Study officials:
affiliation: CHRU of Lille
name: Alexis CORTOT, MD, PhD
role: STUDY_DIRECTOR
affiliation: Centre Oscar Lambret
name: Eric Dansin, MD
role: STUDY_DIRECTOR
References: